DGAP-News

Delenex Therapeutics AG Expands Pipeline

EQS Group-News: Delenex Therapeutics AG / Key word(s): Scientific
publication/Miscellaneous
Delenex Therapeutics AG Expands Pipeline

15.09.2014 / 11:32

---------------------------------------------------------------------

Delenex Therapeutics AG Expands Pipeline with Anti-IL-17A and Anti-IL-1b
PENTRA(R)Body Programs

- Extremely high potency and small size uniquely position products in
dermatological and inflammatory diseases

Schlieren/Zurich, September 15, 2014 - Delenex Therapeutics AG, a clinical
stage biopharmaceutical company primarily developing treatments for
dermatological diseases using its proprietary PENTRA(R)Bodies, today
announced that it has expanded its pipeline with two PENTRA(R)Bodies
targeting interIeukin-17A and interleukin-1b.

Delenex has generated an anti-IL-17A PENTRA(R)Body for the treatment of
dermatological and other inflammatory diseases. IL-17A is a pivotal
interleukin which has been shown to play a key role in such medical
conditions. Systemic administration of anti-IL-17A IgGs is an effective
treatment of psoriasis, psoriatic arthritis and other diseases. The small
size of about 25 kDa of the PENTRA(R)Body and its extraordinary
neutralizing potency (IC50) of < = 5 picomolar allow a unique positioning
as
compared to other anti-IL-17A treatments currently in clinical development.

Delenex' lead candidate neutralizing IL-1b is a PENTRA(R)Body for the
treatment of acne and other inflammatory diseases such as gouty arthritis.
Delenex' anti-IL-1b displays neutralizing potency in the femtomolar IC50
range (< = 600 fM). IL-1b has been shown to be overexpressed in lesions of
acne and to be a key mediator of skin inflammation in this disease that
affects a substantial fraction of the population and demands innovative
treatment modalities, especially in case of moderate-to-severe forms of
acne. In gout, the high potency and small size allow the application of
this PENTRA(R)Body especially for the treatment of gout flares, where a
fast onset and short action of the drug is required.

"The identification of such highly potent PENTRA(R)Bodies in a short period
of time proves once again the power of our technology. PENTRA(R)Bodies are
uniquely positioned vis-à-vis existing therapies and address the increasing
demand for therapies that combine high potency with a favorable safety
profile and cost-efficiency", commented Titus Kretzschmar, PhD, Chief
Scientific Officer at Delenex.

About Delenex Therapeutics AG

Delenex is a privately-held, clinical stage biopharmaceutical company
focused on the development of locally and systemically applied antibody
therapeutics. Delenex aims at extending the benefits of proven antibody
therapeutics to a much larger number of people suffering from psoriasis,
hidradenitis suppurativa, acne and other dermatological and
non-dermatologic, diseases. Delenex' proprietary PENTRA(R)Bodies are small,
highly potent and stable antibody fragments that are superior in
penetrating tissues and in crossing barriers in the human body.
Delenex was founded in September 2009 as a spin-off from ESBATech (now a
Novartis company).

For further details please contact:

Jakob Schlapbach, CFO
Delenex Therapeutics AG
Wagistrasse 27
CH-8952 Schlieren
Phone: [phone]
E-mail: [e-mail]
Website: www.delenex.com



+++++
Additional features:

Document: http://n.equitystory.com/c/fncls.ssp?u=JOKKGEGUSH
Document title: Delenex-expands-pipeline

---------------------------------------------------------------------

15.09.2014 This Corporate News was distributed by EQS Schweiz AG.
www.eqs.com - news archive: http://switzerland.eqs.com/de/News

The issuer is responsible for the contents of the release.

---------------------------------------------------------------------


286996 15.09.2014